LOGIN
No significant difference for improvement of erosive hand OA pain between adalimumab and placebo
October 2018
No significant difference for improvement of erosive hand OA pain between adalimumab and placebo
Study Type:Randomized Trial
OE Level Evidence:1
Journal Level of Evidence:N/A
A randomised double-blind placebo-controlled crossover trial of HUMira (adalimumab) for erosive hand OsteoaRthritis - the HUMOR trial
Osteoarthritis Cartilage. 2018 Jul;26(7):880-887. doi: 10.1016/j.joca.2018.02.899Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
43 patients with erosive hand osteoarthritis were included in a crossover, randomized design to evaluate the efficacy of adalimumab as a treatment option. Patients were randomized to the order in which they received intervention with either adalimumab or placebo for 12 weeks. There was an 8-week washout period between treatment phases. Improvement in patient-reported pain, stiffness, and function ...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.